Licoricesaponin G2

Name: Licoricesaponin G2
Brand: MedChemExpress
SKU: HY-N6983
Rating: 4.5 (1 reviews)

Cat. No.: HY-N6983 Purity: 99.87%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Licoricesaponin G2 is an orally active component found in Licorice. Licoricesaponin G2 significantly ameliorates Bleomycin (HY-108345)-induced pulmonary fibrosis by inhibiting the TNF-α signaling pathway, reducing epithelial-mesenchymal transition, and decreasing extracellular matrix deposition. Licoricesaponin G2 inhibits cancer cells proliferation, migration, inhibits PI3K/AKT/mTOR signaling pathway and increases ROS production. Licoricesaponin G2 can be used for the research of lung cancer and pulmonary fibrosis.

For research use only. We do not sell to patients.

Licoricesaponin G2 Chemical Structure

CAS No. : 118441-84-2

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

View All mTOR Isoform Specific Products:

View All Isoforms

mTOR mTORC1 mTORC2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	IC₅₀	6.9 μM Compound: 194	Hepatotoxicity in D-GaIN induced in Wistar rat model hepatocyte assessed as reduction in PLA2 level Hepatotoxicity in D-GaIN induced in Wistar rat model hepatocyte assessed as reduction in PLA2 level	[PMID: 29353722]

In Vitro

Licoricesaponin G2 (0.5-10 μM; 72 h) reduces the viability of NCI-A549, NCI-H460, and NCI-H446 lung cancer cells in a dose-dependent manner^[1].
Licoricesaponin G2 (1-5 μM; 14 days) dose-dependently inhibits colony formation in NCI-A549, NCI-H460, and NCI-H446 lung cancer cells^[1].
Licoricesaponin G2 (1-5 μM; 3 days) dose-dependently inhibits sphere formation in NCI-A549, NCI-H460, and NCI-H446 lung cancer cells^[1].
Licoricesaponin G2 (1-5 μM) dose-dependently downregulates cancer stem cell markers (CD44, CD133), PI3K/AKT pathway phosphorylated proteins (p-PI3K, p-AKT, p-mTOR), EGFR/STAT3 pathway phosphorylated proteins (p-EGFR, p-STAT3), and ferroptosis markers (SLC7A11, GPX4) in NCI-A549 and NCI-H446 lung cancer cells^[1].
Licoricesaponin G2 (1-5 μM; 48 h) increases the thermal stability of the PIK3R1 protein in NCI-A549 lung cancer cells^[1].
Licoricesaponin G2 (1-5 μM; 24 h) dose-dependently increases intracellular reactive oxygen species levels in NCI-H446 lung cancer cells^[1].
Licoricesaponin G2 (1-5 μM) dose-dependently increases MDA and GSH levels in NCI-H446 lung cancer cells^[1].
Licoricesaponin G2 (1-5 μM) inhibits 3D spheroid formation in NCI-H460 lung cancer cells and dose-dependently downregulates phosphorylated PI3K/AKT pathway proteins (p-PI3K, p-AKT, p-mTOR) in spheroids^[1].
Licoricesaponin G2 shows strong binding affinity to both TNF-α and MMP9 proteins, with docking scores of -4.849 kcal/mol and -6.392 kcal/mol, respectively^[2].
Licoricesaponin G2 (0.2-50 μM; 48 h) reduces viability of A549 human lung carcinoma cells, and also reduces viability of TGF-β₁-stimulated A549 and MRC5 cells at these respective concentrations^[2].
Licoricesaponin G2 (0.8-3.1 μM; 48 h) reverses TGF-β1-induced EMT and ECM accumulation in A549 human lung carcinoma cells by upregulating E-cadherin and downregulating N-cadherin, α-SMA, and Collagen I at both mRNA and protein levels^[2].
Licoricesaponin G2 (6.3-25 μM; 48 h) reverses TGF-β1-induced FMT and ECM accumulation in MRC5 human fetal lung fibroblasts by downregulating α-SMA and Collagen I at both mRNA and protein levels^[2].
Licoricesaponin G2 (0.8-1.6 μM; 24 h) inhibits TGF-β1-induced migration of A549 human lung carcinoma cells^[2].
Licoricesaponin G2 (0.8-12.5 μM; 48 h) inhibits the TNF-α signaling pathway in TGF-β1-stimulated A549 and MRC5 cells, reducing protein levels of TNF-α, p-IKK, p-NFκB, MMP3, and MMP9^[2].
Licoricesaponin G2 (0.05-1.0 mg/plate) does not exhibit antimutagenic activity against MNU in Salmonella typhimurium TA1535^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	NCI-A549, NCI-H460, NCI-H446
Concentration:	0.5, 1, 2.5, 5, 10 μM
Incubation Time:	72 h
Result:	Significantly reduced the viability of A549, H460, and H446 cells at 5 and 10 μM. Decreased viability in a dose-dependent manner.

Western Blot Analysis^[2]

Cell Line:	TGF-β1-stimulated A549 human lung carcinoma cells
Concentration:	0.8, 1.6 μM
Incubation Time:	48 h
Result:	Increased E-cadherin levles. Reduced TGF-β1-increased N-cadherin, α-SMA and Collagen I levels.

In Vivo

Licoricesaponin G2 (10-50 mg/kg; daily; 21 days) dose-dependently inhibits growth of lung cancer NCI-A549 cells xenografts in mice^[1].
Licoricesaponin G2 (50 mg/kg; i.g.,; daily; 14 days) significantly ameliorates Bleomycin (HY-108345)-induced pulmonary fibrosis in male C57/BL6 mice by inhibiting the TNF-α signaling pathway, reducing epithelial-mesenchymal transition, and decreasing extracellular matrix deposition^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c nude mice (female, 4-5 weeks old, 18-22 g, SPF, subcutaneous NCI-A549 cells xenograft model)^[1]
Dosage:	10 mg/kg; 50 mg/kg
Administration:	daily; 21 days
Result:	Reduced final tumor volume and tumor weight in a dose-dependent manner. Reduced CD44 and CD133 protein levels in tumor tissue. Reduced p-PI3K, p-AKT, and p-mTOR levels.

Animal Model:	C57/BL6 (8-week-old male, bleomycin-induced pulmonary fibrosis)^[2]
Dosage:	50 mg/kg
Administration:	p.o.; daily; 14 days
Result:	Reduced bleomycin-induced lung pathological changes including connective tissue proliferation, alveolar structure damage, and inflammatory cell infiltration. Decreased collagen fiber deposition. Upregulated E-cadherin protein expression and downregulated N-cadherin, α-SMA, and Collagen I protein expression. Decreased α-SMA and Collagen I levels in lung tissue. Reduced Bleomycin-induced increases in TNF-α, p-IKK, p-NFκB, MMP3, and MMP9 protein levels in lung tissue.

Molecular Weight

838.93

Formula

C₄₂H₆₂O₁₇

CAS No.

118441-84-2

Appearance

Solid

Color

White to off-white

SMILES

C[C@@]1([C@@]2([H])[C@@]3([C@@]([C@](C)([C@@H](O[C@@]4([H])[C@@H]([C@H]([C@H](O)[C@@H](C(O)=O)O4)O)O[C@]5([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)CC3)CO)([H])CC1)C)[C@]6(C([C@@]7([H])[C@](C)(CC[C@@](C(O)=O)(C)C7)CC6)=CC2=O)C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (119.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1920 mL	5.9600 mL	11.9199 mL
5 mM	0.2384 mL	1.1920 mL	2.3840 mL
10 mM	0.1192 mL	0.5960 mL	1.1920 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (285 KB) SDS (394 KB)

COA (255 KB) HNMR (152 KB) LCMS (92 KB)

Handling Instructions (2659 KB)

References

[1]. Yang X, et al. Based on network pharmacology and experiments to investigate the inhibitory effect of Licoricesaponin G2 on lung cancer tumor growth. J Ethnopharmacol. 2026;357:120950.

[2]. Ma J, et al. Licoricesaponin G2 ameliorates bleomycin-induced pulmonary fibrosis via targeting TNF-α signaling pathway and inhibiting the epithelial-mesenchymal transition. Front Pharmacol. 2024;15:1437231. Published 2024 Sep 5.

[3]. Inami K, et al. Antimutagenic components in Glycyrrhiza against N-methyl-N-nitrosourea in the Ames assay. Nat Prod Res. 2017;31(6):691-695. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1920 mL	5.9600 mL	11.9199 mL	29.7999 mL
	5 mM	0.2384 mL	1.1920 mL	2.3840 mL	5.9600 mL
	10 mM	0.1192 mL	0.5960 mL	1.1920 mL	2.9800 mL
	15 mM	0.0795 mL	0.3973 mL	0.7947 mL	1.9867 mL
	20 mM	0.0596 mL	0.2980 mL	0.5960 mL	1.4900 mL
	25 mM	0.0477 mL	0.2384 mL	0.4768 mL	1.1920 mL
	30 mM	0.0397 mL	0.1987 mL	0.3973 mL	0.9933 mL
	40 mM	0.0298 mL	0.1490 mL	0.2980 mL	0.7450 mL
	50 mM	0.0238 mL	0.1192 mL	0.2384 mL	0.5960 mL
	60 mM	0.0199 mL	0.0993 mL	0.1987 mL	0.4967 mL
	80 mM	0.0149 mL	0.0745 mL	0.1490 mL	0.3725 mL
	100 mM	0.0119 mL	0.0596 mL	0.1192 mL	0.2980 mL